Literature DB >> 23989750

Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease.

Timothy R Elliott1, Barry N Hudspith, Guanghui Wu, Michael Cooley, Gareth Parkes, Beatriz Quiñones, Luke Randall, Robert E Mandrell, Clifton K Fagerquist, Jonathan Brostoff, Neil B Rayment, Alex Boussioutas, Liljana Petrovska, Jeremy D Sanderson.   

Abstract

BACKGROUND: Mucosa-associated Escherichia coli are abundant in inflammatory bowel disease (IBD), but whether these bacteria gain intracellular access within the mucosa is uncertain. If E. coli does gain intracellular access, the contribution of bacterial pathogenicity to this requires further elucidation. This study aimed to quantify and characterize mucosa-associated and intracellular E. coli in patients with IBD and in healthy control subjects (HC).
METHODS: Mucosal biopsies from 30 patients with Crohn's disease (CD), 15 with ulcerative colitis (UC), and 14 HC were cultured with or without gentamicin protection to recover intracellular or mucosa-associated E. coli, respectively. Overall, 40 strains (CD: n = 24, UC: n = 9, and HC: n = 7) were characterized by phylogenetic typing, adhesion and invasion assays, detection of virulence factors, antimicrobial resistance genes, and proteomic analysis.
RESULTS: Mucosa-associated E. coli were more abundant in CD and UC than in HC (2750 versus 1350 versus 230 median colony-forming units per biopsy; P = 0.01). Intracellular E. coli were more prevalent in CD (90%) than in UC (47%) or HC mucosal biopsies (0%) (P < 0.001). Of 24 CD strains, 2 were adherent and invasive, but there were no unifying pathogenicity determinants that could distinguish most CD strains from UC or HC strains, or intracellular isolates from mucosa-associated isolates.
CONCLUSIONS: Intracellular E. coli are more common in CD than in UC and not identified in HC. Most intracellular E. coli did not have characterizing pathogenic features, suggesting a significant role for defects in mucosal immunity or barrier dysfunction in their ability to gain intracellular access.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23989750     DOI: 10.1097/MIB.0b013e3182a38a92

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  19 in total

1.  ER-stress mobilization of death-associated protein kinase-1-dependent xenophagy counteracts mitochondria stress-induced epithelial barrier dysfunction.

Authors:  Fernando Lopes; Åsa V Keita; Alpana Saxena; Jose Luis Reyes; Nicole L Mancini; Ala Al Rajabi; Arthur Wang; Cristiane H Baggio; Michael Dicay; Rob van Dalen; Younghee Ahn; Matheus B H Carneiro; Nathan C Peters; Jong M Rho; Wallace K MacNaughton; Stephen E Girardin; Humberto Jijon; Dana J Philpott; Johan D Söderholm; Derek M McKay
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

Review 2.  Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity.

Authors:  Margarita Martinez-Medina; Librado Jesus Garcia-Gil
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

3.  Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome.

Authors:  Marjorie De la Fuente; Luigi Franchi; Daniela Araya; David Díaz-Jiménez; Mauricio Olivares; Manuel Álvarez-Lobos; Douglas Golenbock; María-Julieta González; Francisco López-Kostner; Rodrigo Quera; Gabriel Núñez; Roberto Vidal; Marcela A Hermoso
Journal:  Int J Med Microbiol       Date:  2014-02-06       Impact factor: 3.473

4.  Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease.

Authors:  Byron P Vaughn; Tommi Vatanen; Jessica R Allegretti; Aiping Bai; Ramnik J Xavier; Joshua Korzenik; Dirk Gevers; Amanda Ting; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 5.  Gut microbiota-derived metabolites in CRC progression and causation.

Authors:  Nishu Dalal; Rekha Jalandra; Nitin Bayal; Amit K Yadav; Minakshi Sharma; Govind K Makharia; Pramod Kumar; Rajeev Singh; Pratima R Solanki; Anil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

6.  Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease.

Authors:  Xochitl C Morgan; Boyko Kabakchiev; Levi Waldron; Andrea D Tyler; Timothy L Tickle; Raquel Milgrom; Joanne M Stempak; Dirk Gevers; Ramnik J Xavier; Mark S Silverberg; Curtis Huttenhower
Journal:  Genome Biol       Date:  2015-04-08       Impact factor: 13.583

7.  Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease.

Authors:  Timothy R Elliott; Neil B Rayment; Barry N Hudspith; Rebecca E Hands; Kirstin Taylor; Gareth C Parkes; Natalie J Prescott; Liljana Petrovska; John Hermon-Taylor; Jonathan Brostoff; Alex Boussioutas; Christopher G Mathew; Stephen A Bustin; Jeremy D Sanderson
Journal:  BMC Gastroenterol       Date:  2015-07-03       Impact factor: 3.067

Review 8.  Microbial imbalance and intestinal pathologies: connections and contributions.

Authors:  Ye Yang; Christian Jobin
Journal:  Dis Model Mech       Date:  2014-10       Impact factor: 5.758

Review 9.  Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies.

Authors:  Allison Agus; Sébastien Massier; Arlette Darfeuille-Michaud; Elisabeth Billard; Nicolas Barnich
Journal:  Biomed Res Int       Date:  2014-12-15       Impact factor: 3.411

10.  Comparative preclinical pharmacokinetics study of 3,3'-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Ekaterina Muyzhnek; Vadim Drukh; Igor Kuznetsov; Olga Pchelintseva
Journal:  EPMA J       Date:  2013-12-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.